Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Lancet (London, England)|December 14, 2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Charlotte Graham, Deborah Yallop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Lancet (London, England)|December 14, 2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Charlotte Graham, Deborah Yallop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
Pageof 12